Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Kay

Showing results (141-150 of 172) with videos related to

Pageof 18
Sort By:
Biologicals : Journal of the International Association of Biological Standardization|October 23, 2012
Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012Jonathan Kay, Brian G Feagan, Micheal S Guirguis, et al.
Lancet (London, England)|June 30, 2009
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trialJosef S Smolen, Jonathan Kay, Mittie K Doyle, et al.
Rheumatology (Oxford, England)|July 11, 2013
The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisDaniel E Furst, Jonathan Kay, Mary Chester Wasko, et al.
RMD Open|November 28, 2025
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studiesHelena Marzo-Ortega, Victoria Navarro-Compan, Maureen Dubreuil, et al.
Annals of the Rheumatic Diseases|August 12, 2010
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase IJulia Funovits, Daniel Aletaha, Vivian Bykerk, et al.
Trials|March 19, 2025
Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trialAlexis Ogdie, Soumya M Reddy, Sarah H Gillespie, et al.
RMD Open|October 8, 2020
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinibJonathan Kay, Masayoshi Harigai, Josh Rancourt, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|September 24, 2015
Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR DatabaseEmilia Gvozdenović, Ron Wolterbeek, Cornelia F Allaart, et al.
Endocrine-Related Cancer|January 7, 2015
HES5 silencing is an early and recurrent change in prostate tumourigenesisCharles E Massie, Inmaculada Spiteri, Helen Ross-Adams, et al.
Clinical and Experimental Rheumatology|September 3, 2016
The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016Kevin L Winthrop, Vibeke Strand, Désiréé M van der Heijde, et al.
Pageof 18

Showing results (141-150 of 172) with videos related to

Sort By:
Pageof 18
Biologicals : Journal of the International Association of Biological Standardization|October 23, 2012
Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012Jonathan Kay, Brian G Feagan, Micheal S Guirguis, et al.
Lancet (London, England)|June 30, 2009
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trialJosef S Smolen, Jonathan Kay, Mittie K Doyle, et al.
Rheumatology (Oxford, England)|July 11, 2013
The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisDaniel E Furst, Jonathan Kay, Mary Chester Wasko, et al.
RMD Open|November 28, 2025
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studiesHelena Marzo-Ortega, Victoria Navarro-Compan, Maureen Dubreuil, et al.
Annals of the Rheumatic Diseases|August 12, 2010
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase IJulia Funovits, Daniel Aletaha, Vivian Bykerk, et al.
Trials|March 19, 2025
Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trialAlexis Ogdie, Soumya M Reddy, Sarah H Gillespie, et al.
RMD Open|October 8, 2020
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinibJonathan Kay, Masayoshi Harigai, Josh Rancourt, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|September 24, 2015
Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR DatabaseEmilia Gvozdenović, Ron Wolterbeek, Cornelia F Allaart, et al.
Endocrine-Related Cancer|January 7, 2015
HES5 silencing is an early and recurrent change in prostate tumourigenesisCharles E Massie, Inmaculada Spiteri, Helen Ross-Adams, et al.
Clinical and Experimental Rheumatology|September 3, 2016
The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016Kevin L Winthrop, Vibeke Strand, Désiréé M van der Heijde, et al.
Pageof 18